NAD-boosting treatment shows no Parkinson's benefit in yearlong trial

A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA.